Trial Profile
Phase III trial for Breast cancer in China
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2018
Price :
$35
*
At a glance
- Drugs Antineoplastics (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 13 Dec 2018 New trial record
- 27 Oct 2018 According to HaiHe Biopharma media release, has recently received an international multi-center phase III clinical trial approval for first-line treatment of breast cancer issued by China's State Drug Administration. It has only been approved for three months from the registration of clinical trials for gastric cancer.